Search - tctmd.com

Displaying 301 - 320 of 392

Sort: Relevancy | Date

News Daily News

New Valvular Heart Disease Guidelines Integrate Catheter-based Interventions

L.A. McKeown

March 20, 2014

News Daily News

CoreValve Reduces Mortality at 1 Year in Patients at Extreme Surgical Risk

March 20, 2014

News Daily News

CoreValve Reduce la Mortalidad al cabo de 1 Año en Pacientes de Riesgo Quirúrgico Extremo

March 20, 2014

News Daily News

La Regurgitación Aórtica se Confirma como un Potente Predictor de la Mortalidad tras TAVR

L.A. McKeown

March 05, 2014

News Daily News

Aortic Regurgitation Confirmed as Powerful Mortality Predictor after TAVR

L.A. McKeown

March 05, 2014

News Daily News

Over the Long Haul, TAVR Appears Better Than Surgery for Women

Caitlin E. Cox

February 19, 2014

News Daily News

Preclinical Data Show Safety, Efficacy of Transcatheter Mitral Valve

Yael L. Maxwell

January 22, 2014

News Conference News TCT 2013

Second-Generation TAVR Device Overcomes Issues of Current Valves

October 31, 2013

News Industry News

Second Generation Transcatheter Aortic Valve Shown to Successfully Address Complications of TAVR

October 31, 2013

News Industry News

BOSTON SCIENTIFIC LOTUS™ VALVE SYSTEM MEETS

October 31, 2013

Presentation TCT 2013

TCT-105. Device-to-Annulus Pre-deployment Angle by Intraoperative Transesophageal Echocardiography Predicts Paravalvular Regurgitation following Transcatheter Aortic Valve...

Presenter: Leo Marcoff

October 29, 2013

Presentation TCT 2013

Reduces Paravalvular Regurgitation

Presenter: Rebecca Hahn

October 28, 2013

Presentation TCT 2013

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Presenter: Samir Kapadia

October 28, 2013

Presentation TCT 2013

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Presenter: Raj Makkar

October 28, 2013

Presentation TCT 2013

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Presenter: Hans Figulla

October 28, 2013

Presentation TCT 2013

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Jonathon Leipsic

October 28, 2013

News Conference News TCT 2013

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

October 28, 2013

News Industry News

Boston Scientific Receives CE Mark For Lotus™ Valve System

October 28, 2013

News Daily News

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

October 11, 2013

News Daily News

Los Pacientes TAVR con Regurgitación Mitral Moderada/Severa tienen un Peor Pronóstico

October 11, 2013

Advertisement

New Valvular Heart Disease Guidelines Integrate Catheter-based Interventions

CoreValve Reduces Mortality at 1 Year in Patients at Extreme Surgical Risk

CoreValve Reduce la Mortalidad al cabo de 1 Año en Pacientes de Riesgo Quirúrgico Extremo

La Regurgitación Aórtica se Confirma como un Potente Predictor de la Mortalidad tras TAVR

Aortic Regurgitation Confirmed as Powerful Mortality Predictor after TAVR

Over the Long Haul, TAVR Appears Better Than Surgery for Women

Preclinical Data Show Safety, Efficacy of Transcatheter Mitral Valve

Second-Generation TAVR Device Overcomes Issues of Current Valves

Second Generation Transcatheter Aortic Valve Shown to Successfully Address Complications of TAVR

BOSTON SCIENTIFIC LOTUS™ VALVE SYSTEM MEETS

TCT-105. Device-to-Annulus Pre-deployment Angle by Intraoperative Transesophageal Echocardiography Predicts Paravalvular Regurgitation following Transcatheter Aortic Valve...

Reduces Paravalvular Regurgitation

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

Boston Scientific Receives CE Mark For Lotus™ Valve System

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

Los Pacientes TAVR con Regurgitación Mitral Moderada/Severa tienen un Peor Pronóstico

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content